Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 24
Filtrar
Más filtros

Medicinas Complementárias
Tipo del documento
Intervalo de año de publicación
1.
Rev. chil. enferm. respir ; 37(1): 11-16, mar. 2021. tab, ilus
Artículo en Español | LILACS | ID: biblio-1388128

RESUMEN

El trasplante de pulmón (TP) es una opción para pacientes pediátricos con enfermedades pulmonares terminales. OBJETIVO: Evaluar resultados y sobrevida de pacientes pediátricos trasplantados de pulmón. MÉTODOS: Análisis retrospectivo de registros clínicos de pacientes TP ≤ 15 años de Clínica Las Condes. Se analizaron datos demográficos, tipo de trasplante, función pulmonar basal y post trasplante, complicaciones precoces y tardías y sobrevida. RESULTADOS: Nueve pacientes < 15 años de edad se han trasplantado. La edad promedio fue 12,7 años. La principal indicación fue fibrosis quística (7 pacientes). El IMC promedio fue de 17,6 y todos estaban con oxígeno domiciliario. El 77% utilizó soporte extracorpóreo intraoperatorio. Las principales complicaciones precoces fueron hemorragia y la disfunción primaria de injerto mientras que las tardías fueron principalmente las infecciones y la disfunción crónica de injerto. Cuatro pacientes han fallecido y la sobrevida a dos años fue de 85%. El trasplante les permitió una reinserción escolar y 3 lograron completar estudios universitarios. CONCLUSIÓN: El trasplante pulmonar es una alternativa para niños con enfermedades pulmonares avanzadas mejorando su sobrevida y calidad de vida.


Lung transplantation (TP) is a treatment option in children with terminal lung diseases. OBJECTIVE: To evaluate the results and survival of pediatrics lung transplant patients. METHODS: Retrospective analysis of clinical records of lung transplantation of patients ≤ 15 years from Clínica Las Condes, Santiago, Chile. Demographic data, type of transplant, baseline and post transplant lung function, early and late complications and survival rate were analyzed. RESULTS: Nine patients ≤ 15 years-old were transplanted. The average age at transplant was 12.7 years. The main indication was cystic fibrosis (7 patients). The average BMI was 17.6 and all the patients were with home oxygen therapy. 77% used extracorporeal intraoperative support. Average baseline FEV1 was 25.2% with progressive improvement in FEV1 of 77% in the first year. The main early complications were hemorrhage and primary graft dysfunction, while late complications were infections and chronic graft dysfunction. Four patients have died and the estimated 2 years survival was 85%. They achieved school reinsertion and three managed to complete university studies. CONCLUSION: Lung transplantation is an alternative for children with advanced lung diseases improving their survival and quality of life.


Asunto(s)
Humanos , Masculino , Femenino , Niño , Adolescente , Trasplante de Pulmón/estadística & datos numéricos , Enfermedades Pulmonares/cirugía , Pediatría , Bronquiolitis Obliterante , Oxigenación por Membrana Extracorpórea , Análisis de Supervivencia , Chile , Estudios Retrospectivos , Estudios de Seguimiento , Trasplante de Pulmón/efectos adversos , Trasplante de Pulmón/mortalidad , Resultado del Tratamiento , Hemorragia Posoperatoria/etiología , Fibrosis Quística , Disfunción Primaria del Injerto/etiología , Hipertensión Pulmonar , Enfermedades Pulmonares/mortalidad
2.
PLoS One ; 15(5): e0232714, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32374770

RESUMEN

Onodera's prognostic nutritional index (PNI) is useful in predicting prognosis of various diseases. But the usefulness of PNI in non-surgical patients has not been sufficiently proven yet. In patients with mycobacterium avium complex pulmonary disease (MAC-PD), malnutrition is an important factor that affects the quality of life and morbidity. Here, we aimed to evaluate whether PNI is related with clinical outcomes in MAC-PD patients. We examined 663 patients diagnosed with MAC-PD between May 2005 and November 2017. PNI score was calculated at the time of diagnosis and treatment initiation, and patients were divided into malnutrition and non-malnutrition groups according to a cut-off PNI score of 45. As the recommended duration of treatment for MAC-PD is 12 months following sputum conversion, treatment duration less than 12 months was defined as treatment intolerance. Survivals were compared with the log-rank test. Multivariate logistic regression and multivariate Cox proportional hazards models were used to estimate the odds ratio (OR) and hazards ratio (HR) for treatment intolerance and mortality, respectively. Of the 306 patients that received treatment, 193 received treatment longer than 12 months. In the multivariable logistic regression model, malnutrition at the time of treatment initiation was related with treatment intolerance (OR: 2.559, 95% confidence interval [CI]: 1.414-4.634, P = 0.002). Patients in the malnutrition group at the time of diagnosis exhibited lower survival (P<0.001) and malnutrition at the time of diagnosis was a significant risk for all-cause mortality (HR: 2.755, 95% CI: 1.610-4.475, P<0.001). Malnutrition, as defined by PNI, is an independent predictor for treatment intolerance and all-cause mortality in patients with MAC-PD.


Asunto(s)
Antibacterianos/uso terapéutico , Enfermedades Pulmonares/tratamiento farmacológico , Enfermedades Pulmonares/microbiología , Desnutrición/diagnóstico , Complejo Mycobacterium avium , Infección por Mycobacterium avium-intracellulare/tratamiento farmacológico , Evaluación Nutricional , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Estimación de Kaplan-Meier , Enfermedades Pulmonares/diagnóstico , Enfermedades Pulmonares/mortalidad , Masculino , Desnutrición/mortalidad , Persona de Mediana Edad , Infección por Mycobacterium avium-intracellulare/diagnóstico , Infección por Mycobacterium avium-intracellulare/microbiología , Infección por Mycobacterium avium-intracellulare/mortalidad , Estado Nutricional , Pronóstico , Calidad de Vida , Estudios Retrospectivos , Factores de Riesgo , Esputo/microbiología , Resultado del Tratamiento
3.
Br J Nutr ; 123(5): 574-582, 2020 03 14.
Artículo en Inglés | MEDLINE | ID: mdl-31779733

RESUMEN

Excessive Ca intakes have been proposed to associate with vascular calcification and a higher risk of prostate cancer. We investigated the associations of supplemental and dietary Ca intake with mortality using data from 497 828 UK Biobank participants. The average follow-up was 4·2 years and 14 255 participants died, 8297 from cancer, 2959 from CVD and 572 from respiratory disease. The use of Ca supplements and milk consumption were associated with differences in mortality in younger (≤65 years) but not in older participants (>65 years, Pinteraction ≤ 0·04 for all comparisons). Among participants <65 years, there was an inverse association between Ca supplementation (OR 0·91, 95 % CI 0·83, 0·99) and milk consumption (OR 0·93, 95 % CI 0·86, 1·00) with respect to all-cause mortality. In the same age group, milk drinkers had lower odds of cancer mortality (OR 0·89, 95 % CI 0·80, 0·98) but Ca supplement use was associated with increased odds of respiratory mortality (OR 1·69, 95 % CI 1·16, 2·74). All associations in participants aged ≥65 years were null after full adjustment. In sensitivity analyses stratified by hormone replacement therapy, Ca supplement use was associated with decreased odds of cancer mortality in users but increased risk in other women (OR 0·81, 95 % CI 0·69, 0·94 v. OR 1·17, 95 % CI 1·01, 1·35, respectively). To conclude, we saw little evidence for harm with dietary or supplemental Ca. Further studies are required to confirm the proposed interaction with hormone replacement therapy and to exclude reverse causation as a determinant in the association between Ca supplements and increased risk of respiratory diseases.


Asunto(s)
Calcio de la Dieta/análisis , Enfermedades Cardiovasculares/mortalidad , Suplementos Dietéticos/análisis , Enfermedades Pulmonares/mortalidad , Leche/estadística & datos numéricos , Neoplasias/mortalidad , Adulto , Anciano , Animales , Bancos de Muestras Biológicas , Enfermedades Cardiovasculares/etiología , Causas de Muerte , Femenino , Humanos , Enfermedades Pulmonares/etiología , Masculino , Persona de Mediana Edad , Neoplasias/etiología , Estudios Prospectivos , Factores de Riesgo , Reino Unido/epidemiología
4.
BMC Infect Dis ; 19(1): 451, 2019 May 22.
Artículo en Inglés | MEDLINE | ID: mdl-31113404

RESUMEN

BACKGROUND: The emergence of leptospirosis-associated severe pulmonary hemorrhagic syndrome (SPHS) with high case fatality has been reported from many countries. Understanding of clinical disease and sequel of SPHS needs larger studies with adequate numbers. The purpose of this study was to describe the characteristics and sequel by different therapeutic approaches for SPHS in Leptospirosis in Sri Lanka. METHODS: This study was conducted at Teaching Hospital-Karapitiya (THK), Galle, Sri Lanka from June 2015 to December 2017. THK is the main tertiary care center for the Southern Province. All confirmed-cases of leptospirosis who presented during this period and were admitted to five medical units of THK were included in this study. SPHS was defined as a patient presenting; haemoptysis, arterial hypoxemia (Acute Lung Injury Score < 2.5), haemoglobin drop (10% from the previous value), or diffused alveolar shadows in the chest radiograph, without alternative explanation other than leptospirosis. RESULTS: Of the 128 MAT confirmed cases of leptospirosis, 111 (86.7%) had acute kidney injury (AKI) whilst SPHS was seen in 80 (62.5%). Patients typically developed SPHS within the first week of illness, mostly on days 4 and 5. The case fatality rate of this study sample was 28.1% (n = 36), while for patients with SPHS, it was 41.5%. Most of the deaths (n = 19) were within the first 3 days of admission (on the same day 8, and within next 48 h 11). Among SPHS patients, 59 received therapeutic plasma exchange (TPE). The survival rate was higher (n = 35, 74.5%) when the TPE was performed within the first 48 h of detecting SPHS compared to patients in whom the procedure was done after 48 h (n = 5, 54.5%). Of the 19 leptosprosis patients with SPHS who did not receive TPE, 17 died (89.5%). However, the group of patients who received TPE was primarily the patients survived beyond day 3. CONCLUSIONS: We observed that during the study period, SPHS was common and the mortality rate was higher in the study area. The treatment modalities tested need further evaluation and confirmation.


Asunto(s)
Hemorragia/etiología , Leptospirosis/complicaciones , Enfermedades Pulmonares/etiología , Lesión Renal Aguda/etiología , Lesión Renal Aguda/terapia , Adulto , Femenino , Hemorragia/mortalidad , Hemorragia/terapia , Hospitales de Enseñanza/estadística & datos numéricos , Humanos , Inmunoglobulinas/uso terapéutico , Leptospirosis/mortalidad , Leptospirosis/terapia , Enfermedades Pulmonares/mortalidad , Enfermedades Pulmonares/terapia , Masculino , Persona de Mediana Edad , Mortalidad , Intercambio Plasmático , Sri Lanka/epidemiología , Síndrome
5.
J Cell Physiol ; 233(5): 4317-4326, 2018 05.
Artículo en Inglés | MEDLINE | ID: mdl-29139549

RESUMEN

Supplementation of 100% oxygen is a very common intervention in intensive care units (ICU) and critical care centers for patients with dysfunctional lung and lung disorders. Although there is advantage in delivering sufficient levels of oxygen, hyperoxia is reported to be directly associated with increasing in-hospital deaths. Our previous studies reported ventricular and electrical remodeling in hyperoxia treated mouse hearts, and in this article, for the first time, we are investigating the effects of hyperoxia on atrial electrophysiology using whole-cell patch-clamp electrophysiology experiments along with assessment of Kv1.5, Kv4.2, and KChIP2 transcripts and protein profiles using real-time quantitative RT-PCR and Western blotting. Our data showed that induction of hyperoxia for 3 days in mice showed larger outward potassium currents with shorter action potential durations (APD). This increase in current densities is due to significant increase in ultrarapid delayed rectifier outward K+ currents (IKur ) and rapidly activating, rapidly inactivating transient outward K+ current (Ito ) densities. We also observed a significant increase in both transcripts and protein levels of Kv1.5 and KChIP2 in hyperoxia treated atrial cardiomyocytes, whereas no significant change was observed in Kv4.2 transcripts or protein. The data presented here further support our previous findings that hyperoxia induces not only ventricular remodeling, but also atrial electrical remodeling.


Asunto(s)
Proteínas de Interacción con los Canales Kv/genética , Canal de Potasio Kv1.6/genética , Enfermedades Pulmonares/terapia , Oxígeno/efectos adversos , Canales de Potasio Shal/genética , Potenciales de Acción/efectos de los fármacos , Animales , Regulación de la Expresión Génica , Atrios Cardíacos/fisiopatología , Mortalidad Hospitalaria , Humanos , Hiperoxia/etiología , Hiperoxia/fisiopatología , Unidades de Cuidados Intensivos , Pulmón/metabolismo , Pulmón/fisiopatología , Enfermedades Pulmonares/complicaciones , Enfermedades Pulmonares/mortalidad , Enfermedades Pulmonares/fisiopatología , Ratones , Miocitos Cardíacos/efectos de los fármacos , Miocitos Cardíacos/patología , Técnicas de Placa-Clamp , Potasio/metabolismo
6.
Cochrane Database Syst Rev ; (8): CD000501, 2016 Aug 22.
Artículo en Inglés | MEDLINE | ID: mdl-27552058

RESUMEN

BACKGROUND: Vitamin A is necessary for normal lung growth and the integrity of respiratory tract epithelial cells. Preterm infants have low vitamin A status at birth and this has been associated with an increased risk of developing chronic lung disease. OBJECTIVES: To evaluate supplementation with vitamin A on the incidence of death or neonatal chronic lung disease and long-term neurodevelopmental disability in very low birth weight (VLBW) infants compared with a control (placebo or no supplementation), and to consider the effect of the supplementation route, dose, and timing. SEARCH METHODS: For the original review and subsequent updates, we searched the Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library), MEDLINE, Science Citation Index, and the Oxford Database of Perinatal Trials. The reference lists of relevant trials, paediatric and nutrition journals, and conference abstracts and proceedings were handsearched up to 2010.For the 2016 update, we used the standard search strategy of the Cochrane Neonatal Review group to search the Cochrane Central Register of Controlled Trials (CENTRAL 2016, Issue 4), MEDLINE via PubMed (1 May 2016), EMBASE (1 May 2016), and CINAHL (1 May 2016). We also searched clinical trials' databases, conference proceedings, and the reference lists of retrieved articles for randomised controlled trials and quasi-randomised trials. SELECTION CRITERIA: Randomised controlled trials comparing vitamin A supplementation with a control (placebo or no supplementation) or other dosage regimens in VLBW infants (birth weight ≤ 1500 grams or less than 32 weeks' gestation). DATA COLLECTION AND ANALYSIS: Two review authors screened the search results, extracted data, and assessed the trials for risk of bias. Results were reported as risk ratios (RR), risk differences (RD), and number needed to treat to benefit (NNTB), all with 95% confidence intervals (CI). Trialists were contacted for additional data. MAIN RESULTS: Eleven trials met the inclusion criteria. Ten trials (1460 infants) compared vitamin A supplementation with a control and one (120 infants) compared different regimens of vitamin A supplementation. Compared to the control group, vitamin A appeared to have a small benefit in reducing the risk of death or oxygen requirement at one month of age (typical RR 0.93, 95% CI 0.88 to 0.99; typical RD -0.05, 95% CI -0.10 to -0.01; NNTB 20, 95% CI 10 to 100; 6 studies, 1165 infants) and the risk of chronic lung disease (oxygen requirement) at 36 weeks' postmenstrual age (typical RR 0.87, 95% CI 0.77 to 0.99; typical RD -0.07, 95% CI -0.13 to -0.01; NNTB 11, 95% CI 6 to 100; 5 studies, 986 infants) (moderate-quality evidence). There was a marginal reduction of the combined outcome of death or chronic lung disease (typical RR 0.92, 95% CI 0.84 to 1.01; typical RD -0.05, 95% CI -0.11 to 0.01; 4 studies, 1089 infants). Neurodevelopmental assessment of 88% of the surviving infants in the largest trial showed no difference between the groups at 18 to 22 months of age, corrected for prematurity (low-quality evidence). There is no evidence to support different vitamin A dosing regimens. No adverse effects of vitamin A supplementation were reported, but it was noted that intramuscular injections of vitamin A were painful. AUTHORS' CONCLUSIONS: Whether clinicians decide to utilise repeat intramuscular doses of vitamin A to prevent chronic lung disease may depend upon the local incidence of this outcome and the value attached to achieving a modest reduction in the outcome balanced against the lack of other proven benefits and the acceptability of the treatment. Information on long-term neurodevelopmental status suggests no evidence of either benefit or harm from the intervention.


Asunto(s)
Enfermedades del Prematuro/prevención & control , Recién Nacido de muy Bajo Peso , Enfermedades Pulmonares/prevención & control , Vitamina A/uso terapéutico , Vitaminas/uso terapéutico , Humanos , Recién Nacido , Recien Nacido Prematuro , Enfermedades del Prematuro/mortalidad , Enfermedades Pulmonares/mortalidad , Ensayos Clínicos Controlados Aleatorios como Asunto
7.
Rev. cientif. cienc. med ; 19(2): 20-26, 2016. ilus
Artículo en Español | LILACS | ID: biblio-959716

RESUMEN

La calidad diagnóstica es el resultado de integrar el conocimiento médico y reconocimiento de los errores clínicos, se alcanza únicamente con la identificación de las causas de muerte; es la correlación clínico patológica la herramienta principal para dicha acción. El objetivo general de la investigación fue determinar la discrepancia clínico-patológica y su relación con otras variables en las autopsias realizadas en la institución. Se revisaron 159 protocolos de autopsia del período comprendido entre enero 2012 y junio 2016, elaborados por el Servicio de Patología del Hospital Escuela Universitario de Tegucigalpa, Honduras. Se excluyeron 36 por no cumplir los criterios de inclusión. Se utilizaron la CIE-10 y la clasificación de Goldman et al. para clasificar las patologías y establecer las discrepancias diagnósticas, respectivamente. El sexo predominante fue el femenino (2,96:1), la edad media fue de 38 años; prevalecieron los diagnósticos de embarazo/parto/puerperio y enfermedades infecciosas y parasitarias. Concluimos que en 46% de los casos existe discrepancia diagnóstica y la glomerulonefritis fue la principal causa de error, seguida de bronconeumonía. Se recomienda estandarizar el protocolo de autopsias y promover sesiones clínico-patológicas periódicas e integrales.


Diagnostic quality is the result of the integration of medical knowledge and recognition of clinical error, achieved only by identifying the cause of death; clinical pathological correlation is the primary tool for this action. The overall objective of this research was to determine clinical pathological discrepancy and its relationship with other variables within the autopsies performed at the institution. 159 autopsy protocols, elaborated by the Department of Pathology of Hospital Escuela Universitario in Tegucigalpa, Honduras, from January 2012 to June 2016, were reviewed. 36 were excluded for not meeting the inclusion criteria. ICD-10 and Goldman et al. modified by Battle criteria were used to classify diseases and establish diagnostic discrepancies, respectively. The majority of patients were female (2.96:1), the mean age was 38 years old; diagnoses of pregnancy/birth/puerperium and infectious and parasitic diseases prevailed. We conclude that diagnostic discrepancies exist in 46% of all cases and glomerulonephritis was the leading cause of error, followed by bronchopneumonia. It is recommended that autopsy protocols be standardized, and integrative clinical pathological sessions are promoted and integral.


Asunto(s)
Autopsia/estadística & datos numéricos , Diagnóstico Clínico , Enfermedades Pulmonares/mortalidad
8.
Ann Surg Oncol ; 21(12): 3963-9, 2014 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-24916747

RESUMEN

BACKGROUND: Obesity has been described as a risk factor for surgical complications and may play a prominent role in the progression, recurrence, and survival rates of various cancers. Our objective was to investigate the impact of being overweight or obese on perioperative and oncologic outcomes after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemoperfusion (HIPEC) for peritoneal carcinomatosis (PC) from mucinous appendiceal neoplasms (MAN). METHODS: From a prospectively maintained database (2001-2010) of CRS/HIPEC for PC from MAN, we evaluated the body mass index (BMI) of patients, categorizing them into normal weight (NW < 25 kg/m(2)), overweight (OW = 25 to 29.9 kg/m(2)), and obese (OB ≥ 30 kg/m(2)). We compared the perioperative and oncologic outcomes among groups. RESULTS: Of the 282 patients in the database, 234 had BMI data available, and 81, 79, and 74 patients were categorized as NW, OW, and OB, respectively. Although there was a trend toward increased risk of overall complications, wound infections, deep vein thrombosis, respiratory and renal complications, and anastomotic leaks in the OW and OB groups, these differences only achieved statistical significance for renal (p = 0.03) and pulmonary (p = 0.02) complications in the OW and OB groups, respectively. The 5-year survival rate for NW, OW, and OB patients was 63.9, 48, and 54.4 %, respectively (p = 0.63). The median time to progression was 21.1 (NW), 21.7 (OW), and 23.9 (OB) months (p = 0.83). CONCLUSIONS: OW and OB patients may have an increased risk of renal and pulmonary complications, respectively. Obesity has no major impact on perioperative mortality and long-term oncologic outcomes in patients undergoing CRS/HIPEC for MAN.


Asunto(s)
Adenocarcinoma Mucinoso/mortalidad , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Neoplasias del Apéndice/mortalidad , Procedimientos Quirúrgicos de Citorreducción/efectos adversos , Hipertermia Inducida/efectos adversos , Enfermedades Renales/mortalidad , Enfermedades Pulmonares/mortalidad , Obesidad/fisiopatología , Adenocarcinoma Mucinoso/complicaciones , Adenocarcinoma Mucinoso/secundario , Adenocarcinoma Mucinoso/terapia , Neoplasias del Apéndice/complicaciones , Neoplasias del Apéndice/patología , Neoplasias del Apéndice/terapia , Índice de Masa Corporal , Quimioterapia del Cáncer por Perfusión Regional , Terapia Combinada , Femenino , Estudios de Seguimiento , Humanos , Enfermedades Renales/diagnóstico , Enfermedades Renales/etiología , Enfermedades Pulmonares/diagnóstico , Enfermedades Pulmonares/etiología , Masculino , Persona de Mediana Edad , Clasificación del Tumor , Estadificación de Neoplasias , Neoplasias Peritoneales/complicaciones , Neoplasias Peritoneales/mortalidad , Neoplasias Peritoneales/secundario , Neoplasias Peritoneales/terapia , Pronóstico , Estudios Prospectivos , Tasa de Supervivencia
9.
PLoS One ; 7(1): e30527, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-22291977

RESUMEN

BACKGROUND: In the last ten years, bioterrorism has become a serious threat and challenge to public health worldwide. Pulmonary anthrax caused by airborne Bacillus anthracis spores is a life-threatening disease often refractory to antimicrobial therapy. Inhaled spores germinate into vegetative forms that elaborate an anti-phagocytic capsule along with potent exotoxins which disrupt the signaling pathways governing the innate and adaptive immune responses and cause endothelial cell dysfunction leading to vascular injury in the lung, hypoxia, hemorrhage, and death. METHODS/PRINCIPAL FINDINGS: Using a murine model of pulmonary anthrax disease, we showed that a nuclear transport modifier restored markers of the innate immune response in spore-infected animals. An 8-day protocol of single-dose ciprofloxacin had no significant effect on mortality (4% survival) of A/J mice lethally infected with B. anthracis Sterne. Strikingly, mice were much more likely to survive infection (52% survival) when treated with ciprofloxacin and a cell-penetrating peptide modifier of host nuclear transport, termed cSN50. In B. anthracis-infected animals treated with antibiotic alone, we detected a muted innate immune response manifested by cytokines, tumor necrosis factor alpha (TNFα), interleukin (IL)-6, and chemokine monocyte chemoattractant protein-1 (MCP-1), while the hypoxia biomarker, erythropoietin (EPO), was greatly elevated. In contrast, cSN50-treated mice receiving ciprofloxacin demonstrated a restored innate immune responsiveness and reduced EPO level. Consistent with this improvement of innate immunity response and suppression of hypoxia biomarker, surviving mice in the combination treatment group displayed minimal histopathologic signs of vascular injury and a marked reduction of anthrax bacilli in the lungs. CONCLUSIONS: We demonstrate, for the first time, that regulating nuclear transport with a cell-penetrating modifier provides a cytoprotective effect, which enables the host's immune system to reduce its susceptibility to lethal B. anthracis infection. Thus, by combining a nuclear transport modifier with antimicrobial therapy we offer a novel adjunctive measure to control florid pulmonary anthrax disease.


Asunto(s)
Carbunco/tratamiento farmacológico , Carbunco/mortalidad , Antiinfecciosos/administración & dosificación , Enfermedades Pulmonares/tratamiento farmacológico , Enfermedades Pulmonares/mortalidad , Transporte Activo de Núcleo Celular/efectos de los fármacos , Animales , Carbunco/complicaciones , Carbunco/patología , Antiinfecciosos/farmacología , Péptidos de Penetración Celular/administración & dosificación , Péptidos de Penetración Celular/farmacología , Ciprofloxacina/administración & dosificación , Ciprofloxacina/farmacología , Citocinas/sangre , Citocinas/metabolismo , Modelos Animales de Enfermedad , Combinación de Medicamentos , Femenino , Enfermedades Pulmonares/etiología , Enfermedades Pulmonares/patología , Proteínas de la Membrana/administración & dosificación , Proteínas de la Membrana/farmacología , Ratones , Péptidos Cíclicos/administración & dosificación , Péptidos Cíclicos/farmacología , Análisis de Supervivencia , Resultado del Tratamiento
10.
Cochrane Database Syst Rev ; (10): CD000501, 2011 Oct 05.
Artículo en Inglés | MEDLINE | ID: mdl-21975731

RESUMEN

BACKGROUND: Vitamin A is necessary for normal lung growth and the integrity of respiratory tract epithelial cells. Preterm infants have low vitamin A status at birth, and this has been associated with increased risk of developing chronic lung disease. OBJECTIVES: To evaluate vitamin A supplementation on the incidence of death and/or neonatal chronic lung disease and long-term neurodevelopmental disability in very low birthweight infants (VLBW); and to consider the effect of the supplementation route, dose, and timing. SEARCH STRATEGY: In August 2011, the Cochrane Central Regsiter of Controlled Trials (Central, The Cochrane Library), MEDLINE, Science Citation Index and the Oxford Database of Perinatal Trials were searched. The reference lists of relevant trials, paediatric and nutrition journals, and conference abstracts and proceedings were handsearched up to 2007. SELECTION CRITERIA: Randomised controlled trials comparing vitamin A supplementation with a control (placebo or no supplementation) or other dosage regimens in VLBW infants (birthweight ≤ 1500 g or < 32 weeks' gestation). DATA COLLECTION AND ANALYSIS: Both review authors screened the search results, extracted data, and assessed the trials' risk of bias. Results were reported as risk ratios (RR), risk differences (RD), and number needed to treat to benefit (NNTB), all with 95% confidence intervals (CI). Trialists were contacted for additional data. MAIN RESULTS: Nine trials met the inclusion criteria, eight compared vitamin A supplementation with a control (1291 infants), and one compared different regimens (120 infants). Compared to the control group, vitamin A appears to be beneficial in reducing death or oxygen requirement at one month of age (RR 0.93, 95% CI 0.88 to 0.99; RD -0.05, 95% CI -0.10 to -0.01; NNTB 20, 95% CI 10 to 100; 1165 infants) and oxygen requirement at 36 weeks' postmenstrual age (RR 0.87, 95% CI 0.77 to 0.98; RD -0.08, 95% CI -0.14 to -0.01; NNTB 13, 95% CI 7 to 100; 824 infants). A trend towards a reduction in death or oxygen requirement at 36 weeks' postmenstrual age was also noted (RR 0.91, 95% CI 0.82 to 1.00; 1001 infants). Neurodevelopmental assessment of 88% of surviving infants in the largest trial showed no differences between the groups at 18 to 22 months of age, corrected for prematurity. The different dosage vitamin A regimens showed similar results. AUTHORS' CONCLUSIONS: Whether clinicians decide to utilise repeat intramuscular doses of vitamin A to prevent chronic lung disease may depend upon the local incidence of this outcome and the value attached to achieving a modest reduction in this outcome, balanced against the lack of other proven benefits and the acceptability of treatment. Information on long-term neurodevelopmental status suggests no evidence of either benefit or harm from the intervention.


Asunto(s)
Enfermedades del Prematuro/prevención & control , Recién Nacido de muy Bajo Peso , Enfermedades Pulmonares/prevención & control , Vitamina A/uso terapéutico , Vitaminas/uso terapéutico , Humanos , Recién Nacido , Recien Nacido Prematuro , Enfermedades del Prematuro/mortalidad , Enfermedades Pulmonares/mortalidad , Ensayos Clínicos Controlados Aleatorios como Asunto
11.
Value Health ; 14(5 Suppl 1): S51-9, 2011.
Artículo en Inglés | MEDLINE | ID: mdl-21839900

RESUMEN

OBJECTIVE: To describe the development and validation of a health economic model (HEM) to address the tobacco disease burden and the cost-effectiveness of smoking cessation interventions (SCI) in seven Latin American countries. METHODS: The preparatory stage included the organization of the research network, analysis of availability of epidemiologic data, and a survey to health decision makers to explore country-specific information needs. The development stage involved the harmonization of a methodology to retrieve local relevant parameters and develop the model structure. Calibration and validation was performed using a selected country dataset (Argentina 2005). Predicted event rates were compared to the published rates used as model inputs. External validation was undertaken against epidemiologic studies that were not used to provide input data. RESULTS: Sixty-eight decision makers were surveyed. A microsimulation HEM was built considering the availability and quality of epidemiologic data and relevant outcomes conceived to suit the identified information needs of decision makers. It considers all tobacco-related diseases (i.e., heart, cerebrovascular and chronic obstructive pulmonary disease, pneumonia/influenza, lung cancer, and nine other neoplasms) and can incorporate individual- and population-level interventions. The calibrated model showed all simulated event rates falling within ± 10% of the sources (-9%-+5%). External validation showed a high correlation between published data and model results. CONCLUSIONS: This evidence-based, internally and externally valid HEM for the assessment of the effects of smoking and SCIs incorporates a broad spectrum of tobacco related diseases, SCI, and benefit measures. It could be a useful policy-making tool to estimate tobacco burden and cost-effectiveness of SCI.


Asunto(s)
Costos de la Atención en Salud , Modelos Económicos , Evaluación de Procesos y Resultados en Atención de Salud/economía , Servicios Preventivos de Salud/economía , Cese del Hábito de Fumar/economía , Fumar/economía , Tabaquismo/economía , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Enfermedades Cardiovasculares/economía , Enfermedades Cardiovasculares/mortalidad , Enfermedades Cardiovasculares/prevención & control , Simulación por Computador , Análisis Costo-Beneficio , Técnicas de Apoyo para la Decisión , Investigación sobre Servicios de Salud , Humanos , América Latina/epidemiología , Enfermedades Pulmonares/economía , Enfermedades Pulmonares/mortalidad , Enfermedades Pulmonares/prevención & control , Persona de Mediana Edad , Programas Nacionales de Salud/economía , Neoplasias/economía , Neoplasias/mortalidad , Neoplasias/prevención & control , Reproducibilidad de los Resultados , Fumar/efectos adversos , Fumar/mortalidad , Prevención del Hábito de Fumar , Tabaquismo/mortalidad , Tabaquismo/terapia , Resultado del Tratamiento , Adulto Joven
12.
Ann Emerg Med ; 58(6): 551-558.e2, 2011 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-21802775

RESUMEN

STUDY OBJECTIVE: The emergency department (ED) is an inherently high-risk setting. Early death after an ED evaluation is a rare and devastating outcome; understanding it can potentially help improve patient care and outcomes. Using administrative data from an integrated health system, we describe characteristics and predictors of patients who experienced 7-day death after ED discharge. METHODS: Administrative data from 12 hospitals were used to identify death after discharge in adults aged 18 year or older within 7 days of ED presentation from January 1, 2007, to December 31, 2008. Patients who were nonmembers of the health system, in hospice care, or treated at out-of-network EDs were excluded. Predictors of 7-day postdischarge death were identified with multivariable logistic regression. RESULTS: The study cohort contained a total of 475,829 members, with 728,312 discharges from Kaiser Permanente Southern California EDs in 2007 and 2008. Death within 7 days of discharge occurred in 357 cases (0.05%). Increasing age, male sex, and number of preexisting comorbidities were associated with increased risk of death. The top 3 primary discharge diagnoses predictive of 7-day death after discharge included noninfectious lung disease (odds ratio [OR] 7.1; 95% confidence interval [CI] 2.9 to 17.4), renal disease (OR 5.6; 95% CI 2.2 to 14.2), and ischemic heart disease (OR 3.8; 95% CI 1.0 to 13.6). CONCLUSION: Our study suggests that 50 in 100,000 patients in the United States die within 7 days of discharge from an ED. To our knowledge, our study is the first to identify potentially "high-risk" discharge diagnoses in patients who experience a short-term death after discharge.


Asunto(s)
Servicio de Urgencia en Hospital/estadística & datos numéricos , Mortalidad , Alta del Paciente/estadística & datos numéricos , Adolescente , Adulto , Factores de Edad , Anciano , Anciano de 80 o más Años , California/epidemiología , Comorbilidad , Intervalos de Confianza , Femenino , Humanos , Enfermedades Renales/mortalidad , Modelos Logísticos , Enfermedades Pulmonares/mortalidad , Masculino , Persona de Mediana Edad , Isquemia Miocárdica/mortalidad , Oportunidad Relativa , Estudios Retrospectivos , Factores de Riesgo , Factores Sexuales , Adulto Joven
13.
Asian Cardiovasc Thorac Ann ; 16(2): 120-3, 2008 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-18381869

RESUMEN

Management of recurrent malignant pleural effusion associated with trapped lung syndrome remains problematic. An alternative treatment using a pleural catheter has been advocated. Between August 1999 and August 2002, 127 patients underwent thoracoscopy for malignant pleural effusion. Of these, 52 (41%) with trapped lung were managed by insertion of a pleural catheter. Mean age was 66 years (range, 42-89 years). The most frequent diagnosis was breast cancer. Spontaneous pleurodesis (drainage < 10 mL) occurred in 25 (48%) patients whose catheter was removed after 30 to 255 days (mean, 93.8 days). Symptomatic relief was achieved in 49 (94%) patients. Mean dyspnea score improved significantly from 3.0 to 1.9. Complications comprised catheter blockage, surgical emphysema, cellulitis, and loculated effusion in 2 patients each. Mean length of hospital stay was 3 days (range, 1-16 days). Median survival was 126 days (range, 10-175 days). We conclude that long-term placement of a pleural catheter provides effective palliation for malignant pleural effusion associated with trapped lung syndrome.


Asunto(s)
Catéteres de Permanencia , Drenaje/instrumentación , Enfermedades Pulmonares/etiología , Cuidados Paliativos , Derrame Pleural Maligno/terapia , Adulto , Anciano , Anciano de 80 o más Años , Neoplasias de la Mama/complicaciones , Neoplasias de la Mama/terapia , Drenaje/efectos adversos , Disnea/etiología , Disnea/terapia , Femenino , Estudios de Seguimiento , Humanos , Estimación de Kaplan-Meier , Tiempo de Internación , Enfermedades Pulmonares/complicaciones , Enfermedades Pulmonares/mortalidad , Enfermedades Pulmonares/patología , Enfermedades Pulmonares/terapia , Masculino , Mesotelioma/complicaciones , Mesotelioma/terapia , Persona de Mediana Edad , Cooperación del Paciente , Selección de Paciente , Derrame Pleural Maligno/complicaciones , Derrame Pleural Maligno/etiología , Derrame Pleural Maligno/mortalidad , Derrame Pleural Maligno/patología , Pleurodesia , Calidad de Vida , Recurrencia , Síndrome , Cirugía Torácica Asistida por Video , Factores de Tiempo , Resultado del Tratamiento
14.
Rev. chil. pediatr ; 79(1): 36-44, feb. 2008. graf, tab
Artículo en Español | LILACS | ID: lil-491800

RESUMEN

Objective: Characterize mortality and associated factors in Chilean prematures born < 32 weeks of gestational age (GA) and treated with exogenous surfactant. Method: Cohort of newborns (n = 2 868) registered between 1998-2005 in the database of the Surfactant National Program. The association of gestational and neonatal variables with mortality was estimated through survival analysis and logistic regression. Results: Global mortality was 35 percent, varying by GA from 86.7 percent (< 25 weeks) to 12.6 percent (32 weeks). There was a clear decrease of mortality during the study period, along with a fall in the gestational age and birth weight (BW) of the patients who died (1 021 g +/- 295 to 854 g +/- 258) and GA (27.7 +/- 2.1 to 26.5 +/- 23) during this period. Pulmonary hemorrhage (PH) was the most important factor associated to mortality, so we decided to stratify the analysis by this condition. In children with PH, the mortality estimated risk lower as the GA increased (OR= 0.73; CI95 0.57-0.93) and every 100 g of additional BW (OR= 0.74; CI95 0.63-0.88). Children not affected by PH also had their OR diminished with major GA (OR= 0.82; CI95 0.76-0.90) and more BW (OR= 0.84; CI95 0.79 - 0.89). In addition, the OR decreased with better Apgar 5 min score (OR= 0.80; CI95 0.75-0.85), use of prenatal corticoids (OR= 0.71; CI95 0.56-0.90) and was higher in boys (OR= 1.36; CI95 1.08-1.71). Conclusions: Mortality in premature newborns decreased 15 percent during this period. Inmaturity and extreme low birth weight factors constitute a challenge to improve survival and avoid further complications like PH.


Objetivo: Caracterizar la mortalidad y factores asociados en prematuros chilenos < 32 semanas de edad gestacional (EG) receptores de surfactante exógeno. Pacientes y Métodos: Cohorte de neonatos 1998-2005 (n = 2 868) de la base de datos del Programa Nacional de Surfactante. Se estimó la mortalidad y su relación con variables maternas, del embarazo y neonatales mediante análisis de sobrevida y regresión logística. Resultados: La mortalidad global fue 35 por ciento, variando por EG entre 86,7 por ciento (< 25 semanas) y 12,6 por ciento (32 semanas). La mortalidad descendió en el período, reduciéndose también el peso de nacimiento (PN) de los fallecidos (1 02 lg +/- 295 a 854 g +/- 258) y su EG (27,7 +/- 2,1 a 26,5 +/- 2,3). La hemorragia pulmonar (HP) fue el factor más importante asociado a mortalidad, por lo que se estratificó el análisis por esa condición. En niños con HP, cada semana adicional de EG disminuye el riesgo de morir (OR: 0,73; IC95 0,57-0,93), así como por cada 100 g de peso adicional (OR: 0,74; IC95 0,63-0,88). Sin HP, el riesgo disminuye con mayor EG (OR: 0,82; IC95 0,76-0,90), mayor PN (OR: 0,84; IC95 0,79-0,89), mejor puntuación Apgar 5 minutos (OR: 0,80; IC95 0,75-0,85) y uso de corticoide prenatal (OR: 0,71; IC95 0,56-0,90), siendo significativamente mayor en varones (OR: 1,36; IC(95)1,08-1,71). Conclusiones: En el período, la mortalidad en prematuros disminuyó en 15 por ciento. La inmadurez y extremo bajo peso de niños actualmente viables, plantean importantes desafíos para mejorar su sobrevida y evitar complicaciones, entre ellas, la HP.


Asunto(s)
Humanos , Recién Nacido , Enfermedades Pulmonares/mortalidad , Enfermedades Pulmonares/tratamiento farmacológico , Recien Nacido Prematuro , Surfactantes Pulmonares/uso terapéutico , Chile/epidemiología , Hemorragia/mortalidad , Incidencia , Mortalidad Infantil , Insuficiencia Respiratoria/epidemiología , Insuficiencia Respiratoria/tratamiento farmacológico , Modelos Logísticos , Programas Nacionales de Salud , Factores de Riesgo , Análisis de Supervivencia
15.
Ann Trop Paediatr ; 24(2): 117-31, 2004 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-15186540

RESUMEN

The World Health Organization strategies, Integrated Management of Childhood Illness and Practical Approach to Lung health provide assessment and management guidelines for health workers in developing countries. We reviewed issues important to lung health in adolescents to highlight whether differences in factors such as adolescent behaviour have consequences for the development of case management guidelines, to form a bridge between guidelines for younger children and for adults and to make suggestions for further study. Pneumonia, asthma and tuberculosis are the leading lung health problems in adolescents. As countries industrialise, the importance of asthma mortality and morbidity increases as that of pneumonia and pulmonary tuberculosis decreases. Guidelines for managing pneumonia and asthma in children and adults in developing and developed countries should be adaptable for use in adolescents in developing countries, although more information is needed on predictors of severity such as respiratory rate cut-offs, level of fever, hypotension, malnutrition and level of consciousness. The effectiveness of low-cost treatment for asthma should be explored further. HIV and the global resurgence of tuberculosis pose significant challenges for improving adolescent lung health, and prevention of smoking initiation during adolescence is a priority goal of any integrated approach to improving lung health.


Asunto(s)
Servicios de Salud del Adolescente/organización & administración , Prestación Integrada de Atención de Salud/organización & administración , Países en Desarrollo , Enfermedades Pulmonares/terapia , Adolescente , Conducta del Adolescente , Adulto , Asma/epidemiología , Asma/mortalidad , Asma/terapia , Niño , Prestación Integrada de Atención de Salud/métodos , Países en Desarrollo/estadística & datos numéricos , Infecciones por VIH/epidemiología , Infecciones por VIH/terapia , Humanos , Inmunización , Enfermedades Pulmonares/epidemiología , Enfermedades Pulmonares/mortalidad , Morbilidad , Neumonía/epidemiología , Neumonía/mortalidad , Neumonía/terapia , Tuberculosis Pulmonar/epidemiología , Tuberculosis Pulmonar/mortalidad , Tuberculosis Pulmonar/terapia
16.
J Vasc Surg ; 36(5): 988-91, 2002 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-12422110

RESUMEN

PURPOSE: The purpose of this study was to compare the cardiopulmonary morbidity and mortality rates after endovascular abdominal aortic aneurysm (EAAA) repair with local anesthesia (LA) with intravenous sedation versus general anesthesia (GA). METHODS: Data from patients who underwent elective infrarenal EAAA repair between June 1996 and October 2000 were retrospectively reviewed. Patients with two or more Eagle clinical cardiac risk factors were considered to be at increased risk for a major postoperative cardiac event. Univariate and multivariate analyses for major cardiac and pulmonary morbidity and mortality rates were analyzed with respect to anesthetic type (GA versus LA), age, size of aneurysm, mean number of Eagle risk factors, and presence of two or more cardiac risk factors. RESULTS: Two hundred twenty-nine patients underwent EAAA repair. The GA (158 patients) and LA (71 patients) groups were significantly different with respect to mean age (73 versus 76 years; P =.01) and mean number of cardiac risk factors per patient (1.2 versus 1.6; P =.002). No difference was seen in the overall cardiopulmonary complication rate (13% for GA and 19% for LA; P =.3), pulmonary complication rate (3.8% for GA and 7% for LA; P =.3), or cardiopulmonary mortality rate (3.2% for GA and 2.8% for LA; P =.9). The major cardiac event rate was higher in patients with two or more Eagle risk factors (22%) versus those patients with one or less Eagle risk factors (3.4%; P <.001), irrespective of anesthetic type. In analysis of patients with one or less Eagle risk factors, no difference was seen in the major cardiac event rate by anesthetic type (3% for GA and 5% for LA; P =.6). Also, no difference was seen in major cardiac events in patients with two or more Eagle risk factors by anesthetic type (24% for GA and 22% for LA). On multivariate analysis, the mean number of Eagle risk factors per patient (P <.0001) and the presence of two or more Eagle risk factors were associated with major cardiac and cardiopulmonary complications, whereas age, size of AAA, and anesthetic type were not. CONCLUSION: No difference exists in overall cardiac and pulmonary morbidity and mortality rates after EAAA repair in comparison of GA and LA. The presence of two or more preoperative cardiac risk factors significantly increases the risk of a major postoperative cardiac event.


Asunto(s)
Anestesia General , Anestesia Local , Aneurisma de la Aorta Abdominal/cirugía , Cardiopatías/epidemiología , Enfermedades Pulmonares/epidemiología , Complicaciones Posoperatorias/epidemiología , Anciano , Cardiopatías/mortalidad , Humanos , Enfermedades Pulmonares/mortalidad , Morbilidad , Análisis Multivariante , Complicaciones Posoperatorias/mortalidad , Factores de Riesgo , Tasa de Supervivencia
17.
Epidemiol Rev ; 23(2): 231-47, 2001.
Artículo en Inglés | MEDLINE | ID: mdl-12192735

RESUMEN

Toxic oil syndrome burst upon the scene in Spain in May of 1981, draining the resources of a newly evolving political and social medicine system. The vehicle of the causative toxic agent was identified as an illicit oil that had been diverted from industrial use and refined in order to remove the aniline denaturant, and that was sold in unlabeled 5-liter containers by itinerant salesmen. Over 20,000 people were ultimately affected, and over 1,200 deaths from all causes have been recorded in the affected cohort. The epidemiologic investigation of toxic oil syndrome involved all facets of investigative and analytical work; from visits to factories and interviewing workers, to sophisticated chemical and statistical analytical techniques. This investigation serves as a further illustration that data and information of all types, and from a wide range of fields, need to be systematically collected and evaluated in order to best resolve an epidemiologic mystery. Astute clinical observation of the patients, however, led to the hypothesis that toxic oil syndrome was a result of a toxic exposure. In this and other epidemics of unknown etiology, clinical observation and the intense scrutiny of patients' histories, signs, and symptoms by treating clinicians have often led to hypotheses that could be tested epidemiologically. When there are medical unknowns, the role of the astute clinician continues to be crucial. The toxic oil syndrome epidemic is an example of how even a developed country can be affected by a massive epidemic of environmental origin if failures occur in the systems that control and regulate the food supply or other consumer products. However, such failures could occur anywhere that large commercial networks operate on the regulatory edge, and if these business lack an in depth knowledge of the consequences of alterations in manufacturing conditions. Such was the case with eosinophilia-myalgia syndrome as well, when apparently minor alterations in manufacturing conditions of L-tryptophan led to an increase in impurities in the product that were later associated with the illness. These risks are even greater in countries with few or inconsistent control systems, making the food and drug supply potential portals of entry for serious health hazards, as is further exemplified by the tragic episode of pediatric renal failure in Haiti associated with a legitimate consumer product, paracetamol elixir, that had been manufactured using a fraudulently supplied toxic ingredient, diethylene glycol (81). The potential toxicants in the adulterated rapeseed oil were present in extremely small amounts. If fatty acid anilides or related compounds are indeed the etiologic agents in toxic oil syndrome, then these compounds must be extremely toxic at the parts per million concentrations at which they were found. Further, the roles of causative agents in the development of disorders such as scleroderma, eosinophilic fasciitis, eosinophilic perimyositis, and other similar diseases are unknown, but scientists can speculate that some sort of low level environmental agent may play a role if such extremely small quantities of contaminants are indeed capable of causing disease. Although the exact identity of the etiologic agent in toxic oil syndrome remains unknown, work on toxic oil syndrome continues. Follow-up clinical studies and long-term mortality studies are under way. Investigation of the mechanisms involved in toxic oil syndrome continues. The identification of suspect chemical compounds, their characterization, and effects will hopefully one day contribute to the prevention of other similar diseases.


Asunto(s)
Brotes de Enfermedades , Eosinofilia/inducido químicamente , Enfermedades Musculares/inducido químicamente , Aceites de Plantas/envenenamiento , Compuestos de Anilina/efectos adversos , Brassica rapa/envenenamiento , Eosinofilia/epidemiología , Eosinofilia/mortalidad , Diseño de Investigaciones Epidemiológicas , Ácidos Grasos Monoinsaturados , Femenino , Contaminación de Alimentos , Humanos , Enfermedades Pulmonares/inducido químicamente , Enfermedades Pulmonares/epidemiología , Enfermedades Pulmonares/mortalidad , Masculino , Enfermedades Musculares/epidemiología , Enfermedades Musculares/mortalidad , Aceite de Brassica napus , Factores de Riesgo , España/epidemiología , Síndrome
18.
Am J Public Health ; 85(4): 535-40, 1995 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-7702118

RESUMEN

OBJECTIVES: To update mortality risks for Navajo uranium miners, a retrospective cohort mortality study was conducted of 757 Navajos from the cohort of Colorado Plateau uranium miners. METHODS: Vital status was followed from 1960 to 1990. Standardized mortality ratios were estimated, with combined New Mexico and Arizona non-White mortality rates used for comparison. Cox regression models were used to evaluate exposure-response relationships. RESULTS: Elevated standardized mortality ratios were found for lung cancer (3.3), tuberculosis (2.6), and pneumoconioses and other respiratory diseases (2.6). Lowered ratios were found for heart disease (0.6), circulatory disease (0.4), and liver cirrhosis (0.5). The estimated relative risk for a 5-year duration of exposure vs none was 3.7 for lung cancer, 2.1 for pneumoconioses and other respiratory diseases, and 2.0 for tuberculosis. The relative risk for lung cancer was 6.9 for the midrange of cumulative exposure to radon progeny compared with the least exposed. CONCLUSIONS: Findings were consistent with those from previous studies. Twenty-three years after their last exposure to radon progeny, these light-smoking Navajo miners continue to face excess mortality risks from lung cancer and pneumoconioses and other respiratory diseases.


Asunto(s)
Indígenas Norteamericanos/estadística & datos numéricos , Enfermedades Pulmonares/mortalidad , Minería , Enfermedades Profesionales/mortalidad , Uranio/efectos adversos , Adulto , Anciano , Anciano de 80 o más Años , Estudios de Cohortes , Relación Dosis-Respuesta en la Radiación , Humanos , Neoplasias Pulmonares/mortalidad , Masculino , Persona de Mediana Edad , Neoplasias Inducidas por Radiación/mortalidad , Exposición Profesional/efectos adversos , Exposición Profesional/análisis , Neumoconiosis/mortalidad , Análisis de Regresión , Estudios Retrospectivos , Factores de Riesgo , Sudoeste de Estados Unidos/epidemiología , Tuberculosis Pulmonar/mortalidad
19.
Langenbecks Arch Chir ; 380(1): 37-42, 1995.
Artículo en Inglés | MEDLINE | ID: mdl-7707849

RESUMEN

The quality of perioperative treatment for patients undergoing thoracic surgery is of the utmost importance for postoperative morbidity and mortality. Hence, it was the purpose of this study to examine various aspects of our own procedure. The clinical course following 812 successive thoracotomies in 792 patients over a period of 3 years was documented and analysed. The overall complication rate was found to be 19.7%, with a mortality of 3.8% over a 30-day period. Secretostasis, atelectasis and pneumonia were the most common complications. Owing to the predeposition of autologous blood, the percentage of patients requiring allogeneic blood transfusion was reduced from 27% to 9%. There was no evidence suggesting an increase in the complication rate or a longer stay in hospital. Perioperative antibiotic prophylaxis has reduced postoperative wound infection significantly. Similar reductions in the FEV1 are recorded following thoracic surgery, irrespective of the amount of lung tissue resected. This observation indicates that the remaining lung tissue is severely compromised throughout the postoperative period and that the surgical trauma alone is a major factor influencing postoperative pulmonary function for at least 2 weeks.


Asunto(s)
Cuidados Posoperatorios/métodos , Complicaciones Posoperatorias/terapia , Enfermedades Torácicas/cirugía , Toracotomía , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Antibacterianos/administración & dosificación , Transfusión de Sangre Autóloga , Femenino , Estudios de Seguimiento , Volumen Espiratorio Forzado/fisiología , Humanos , Enfermedades Pulmonares/mortalidad , Enfermedades Pulmonares/cirugía , Neoplasias Pulmonares/mortalidad , Neoplasias Pulmonares/cirugía , Masculino , Persona de Mediana Edad , Complicaciones Posoperatorias/mortalidad , Premedicación , Garantía de la Calidad de Atención de Salud , Infección de la Herida Quirúrgica/mortalidad , Infección de la Herida Quirúrgica/terapia , Tasa de Supervivencia , Enfermedades Torácicas/mortalidad
20.
Arch Phys Med Rehabil ; 74(12): 1358-61, 1993 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-8018145

RESUMEN

Pulmonary complications are the major causes of morbidity and mortality for persons with cervical spinal cord injury. Diminished ability to cough constitutes a major contribution to the high incidence of pulmonary morbidity in this population. This article reports preliminary results for a new technique for providing assisted cough in this population. In this study, efficacy of cough (as measured by peak expiratory flow rate) was measured under three conditions: volitionally with no assistance, with manual assist of a therapist, and with electrical stimulation of abdominal muscles. Coughs produced by electrical stimulation were approximately as effective as manually assisted coughs. The results suggest this technique is worthy of more detailed study and may be a potentially effective new modality for assisting spinal cord injured persons to clear their airways.


Asunto(s)
Terapia por Estimulación Eléctrica/métodos , Enfermedades Pulmonares/terapia , Terapia Respiratoria/métodos , Traumatismos de la Médula Espinal/complicaciones , Terapia Asistida por Computador/métodos , Músculos Abdominales , Adulto , Terapia por Estimulación Eléctrica/instrumentación , Estudios de Evaluación como Asunto , Femenino , Humanos , Enfermedades Pulmonares/etiología , Enfermedades Pulmonares/mortalidad , Enfermedades Pulmonares/fisiopatología , Masculino , Persona de Mediana Edad , Depuración Mucociliar , Ápice del Flujo Espiratorio , Terapia Asistida por Computador/instrumentación
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA